FDA LAW BLOG

On January 7, 2025, the U.S. Food and Drug Administration ("FDA" or "Agency") released a long-awaited guidance titled, "Communications From Firms to Health Care Providers Regarding Scientific Information on Unapproved Uses of Approved/Cleared Medical Products: Questions and Answers" (the "Guidance").[1] The Guidance is a finalized version of the draft guidance released in 2023 (the "Draft Guidance"), which we covered here, and updates FDA's collection of guidances on the topic, including its 2014 draft guidance titled, "Distributing Scientific and Medical Publications on Unapproved New Uses - Recommended Practices" (the "2014 Draft Guidance")[2] and its 2009 guidance titled, "Good Reprint Practices for the Distribution of Medical Journal Articles and Medical or Scientific Reference Publications on Unapproved New Uses of Approved Drugs and Approved or Cleared Medical Devices" (the "2009 Guidance").[3]Continue Reading Finally, FDA's Final Word on Unapproved Use Communications... Earlier..

Primary location: Los Angeles United States